Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside tumor cells to SN‑38, an active metabolite that binds to the DNA‑topoisomerase I complex. This binding prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing cancer cell death.

The dose of Irinotecan Accord is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, treatment protocol, and overall health status. Specific dosing regimens are determined by the treating physician and should not be altered without medical guidance.

Irinotecan is classified as a high‑risk medication for pregnancy and breastfeeding. It should only be used if the potential benefit to the mother outweighs the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class and is often combined with fluoropyrimidines such as 5‑fluorouracil. Compared with oxaliplatin‑based regimens, Irinotecan‑based therapy may have a different toxicity profile, with more frequent diarrhea and neutropenia but less peripheral neuropathy. Choice of regimen depends on prior therapy, patient tolerance, and oncologist assessment.

Irinotecan Accord should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until preparation. During handling, use aseptic technique and follow institutional guidelines for intravenous cytotoxic agents.

Irinotecan Accord is administered by intravenous infusion, typically over 30 to 90 minutes depending on the specific protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring of vital signs and readiness to manage any infusion‑related reactions.

The most serious risks include severe neutropenia or febrile neutropenia, which can predispose to life‑threatening infections, and severe diarrhea or colitis that may lead to dehydration and electrolyte imbalance. Hepatic toxicity, allergic reactions, and rare pulmonary complications also require prompt medical attention.

Patients with known hypersensitivity to Irinotecan or any of its excipients should avoid the drug. It is also contraindicated in individuals with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Caution is advised for patients taking strong CYP3A4 or UGT1A1 inhibitors, and it should be avoided in pregnancy unless absolutely necessary.